13F Holdings
中文EN

ACRS Aclaris Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1557746 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-59.3%
TTM net income YoY43.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR-33.2%
Net income 3-yr CAGR—

Margins

Gross margin79.2%
Operating margin-1,414.0%
Net margin-1,244.1%
FCF margin-1,176.6%
EBITDA margin-1,407.5%

Returns

ROE-55.5%
ROA-40.7%
ROIC (approx.)-59.3%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets22.8%
Debt / equity0.00x
Current ratio5.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.83M$18.72M$31.25M$29.75M$6.76M
Cost of revenue$2.09M$2.79M$3.42M$4.02M$4.71M
Gross profit$5.74M$15.93M$27.83M$25.73M$2.05M
R&D expense$52.65M$33.59M$98.38M$77.81M$43.81M
SG&A expense$21.97M$22.20M$32.41M$25.13M$23.62M
Operating income-$76.38M-$141.93M-$97.36M-$89.85M-$89.72M
Pretax income-$64.92M-$132.06M-$88.85M-$86.91M-$90.86M
Income tax——-$367,000——
Net income-$64.92M-$132.06M-$88.48M-$86.91M-$90.86M
EBITDA-$75.92M-$141.12M-$96.49M-$89.06M-$88.80M
EPS (basic)-0.53-1.71-1.27-1.33-1.60
EPS (diluted)-0.53-1.71-1.27-1.33-1.60
Weighted avg. shares (diluted)122.56M77.30M69.81M65.21M56.73M
Balance sheet
Cash & equivalents$19.96M$24.57M$39.88M$45.28M$27.35M
Short-term investments$70.79M$89.02M$79.23M$172.29M$164.06M
Receivables—$318,000$298,000$484,000$623,000
Current assets$96.32M$125.95M$128.86M$231.55M$205.03M
PP&E, net$761,000$1.01M$1.62M$1.10M$1.33M
Intangibles——$269,000$6.97M$7.05M
Total assets$160.46M$220.33M$197.41M$254.60M$251.21M
Current liabilities$28.64M$31.60M$30.95M$21.94M$22.93M
Total liabilities$57.38M$64.77M$40.23M$56.98M$53.87M
Shareholders' equity$103.08M$155.55M$157.18M$197.62M$197.34M
Shares outstanding120.50M107.85M70.89M66.69M61.23M
Cash flow statement
Operating cash flow-$47.11M-$20.07M-$78.33M-$67.57M-$52.13M
Capital expenditure$111,000$121,000$1.31M$605,000$308,000
Free cash flow-$47.22M-$20.20M-$79.63M-$68.17M-$52.44M
Investing cash flow$48.37M-$69.77M$46.22M$12.63M-$167.63M
Financing cash flow-$5.86M$74.54M$26.71M$72.87M$225.05M
Depreciation & amortization$454,000$807,000$863,000$797,000$923,000
Stock-based compensation$12.38M$10.86M$20.54M$15.04M$14.06M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.